Anza

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anza

Property Description
Active Ingredients Amiloride and Hydrochlorothiazide
Form Tablet
Pharmacological Class Diuretic and Antihypertensive Agent
General Purpose Fluid retention reduction and blood pressure support
Origin Synthetic

Anza: Definition and Pharmacological Class

Anza is a prescription-only, fixed-dose combination medication belonging to the pharmacological classes of diuretics (water pills) and antihypertensive agents. Its fundamental identity is defined by the union of two distinct, synthetically derived active ingredients: Amiloride and Hydrochlorothiazide. This product is supplied as an oral tablet for systemic action, establishing it as a primary therapeutic approach where combined diuretic and blood pressure regulation activity is required. The inclusion of this combination on the World Health Organization (WHO) Model List of Essential Medicines confirms its established role in foundational therapy. The strategy of combining these two diuretic classes is a recognized approach for comprehensive fluid management.

Composition and Drug Form: A Dual-Action Tablet

The core composition of Anza involves the two components acting through different physiological pathways. Hydrochlorothiazide is classified as a thiazide diuretic, recognized for its ability to increase the excretion of both sodium and water. Amiloride, conversely, functions as a potassium-sparing diuretic. The formulation strategically pairs these two agents to achieve a superior, synergistic effect in reducing fluid volume. This pairing provides a critical counterbalance, as the Amiloride component is specifically included to prevent the excessive potassium loss that may occur in individuals receiving a thiazide diuretic alone. This combination strategy is a clinically recognized method to stabilize key electrolytes while achieving the desired reduction in fluid volume.

General Purpose: Supporting Cardiovascular Function

The general purpose of this medication is the management of excessive fluid retention and the support of regulated blood pressure. By facilitating the combined and sustained removal of excess sodium and water from the body via renal action, the medicine helps decrease the overall volume of fluid circulating in the blood vessels. This sustained reduction in fluid load and vascular pressure is instrumental in maintaining fluid balance, thereby supporting overall cardiovascular health. Clinically recognized for its sustained efficacy, this medication is typically used in scenarios requiring long-term, stable control of fluid volume.

Regulatory References

  1. NIH National Library of Medicine

What side effects are possible with Anza?

Side Effects and Safety Information

Anza is associated with a risk profile that includes both common and serious adverse reactions, as detailed in regulatory documents.

Common Adverse Reactions

The most frequently reported adverse reactions (ge 10%) generally involve the gastrointestinal and nervous systems. These very common reactions include:

  • Constipation
  • Nausea and Vomiting
  • Somnolence (drowsiness)
  • Headache

Serious and Clinically Significant Risks

Official safety labeling, including a Boxed Warning from the FDA, highlights several serious risks that may lead to death or severe injury:

  • Life-threatening Respiratory Depression: This is a risk even at recommended doses, with the highest risk upon initiation of therapy or following a dose increase. Fatal cases have been documented.
  • Accidental Exposure: Inadvertent ingestion by a child can result in a fatal overdose.
  • Risk of Abuse and Addiction: The medication carries a high potential for abuse, misuse, and addiction, which can result in overdose and death.
  • Central Nervous System (CNS) Depressants: Profound sedation, respiratory depression, coma, and death can result from co-administration with other CNS depressants, including alcohol. Prescribers must use caution and consider dose adjustments for one or both agents.

Safety Restrictions and Monitoring

The drug is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma, or known or suspected gastrointestinal obstruction.

Use requires close monitoring in populations at increased risk for respiratory depression, such as the elderly, debilitated patients, and those with chronic pulmonary disease. Patients must also be cautioned against driving or operating heavy machinery due to the risk of somnolence.

Overdose and Emergency Response

The official regulatory profile for Anza overdose is defined by the exaggerated effects of its diuretic components, leading to two primary concerns. Overdose is clinically characterized by manifestations of profound fluid and volume depletion, including severe hypotension (low blood pressure), dizziness, and physical signs of dehydration and weakness. A critical, life-threatening risk documented in prescribing information is the potential for severe Hyperkalemia (dangerously high potassium levels) due to the amiloride component. This major electrolyte imbalance can lead to serious cardiovascular complications, specifically potentially fatal cardiac arrhythmias.

Due to the severity of these potential outcomes, regulatory guidance mandates that immediate medical attention be sought for any suspected overdose, particularly if signs such as collapse, difficulty breathing, or seizure are present. As no specific antidote is known, the officially documented management approach is symptomatic and supportive treatment. This includes measures like gastric lavage or activated charcoal if recent, and continuous monitoring of the patient's fluid status, blood pressure, and cardiac function to manage and correct critical electrolyte shifts. Special consideration is also noted for patients with pre-existing renal impairment, who may face increased severity.

Therapeutic Uses of Anza

What Anza Treats: Main Uses and Benefits

Anza is commonly used across therapeutic domains, providing supportive relief for symptoms related to systemic imbalance and heightened physiological activity. The medication is considered relevant in conditions involving episodic or fluctuating manifestations, including essential hypertension (high blood pressure), systemic fluid overload (edema) associated with Congestive Heart Failure, and fluid buildup related to liver cirrhosis.

Therapeutic Focus and Benefits

Anza is generally used to help manage essential hypertension and supports the reduction of elevated arterial pressure. This therapeutic action supports the long-term management of conditions marked by increased physiological stress. Furthermore, it addresses symptom clusters that may become intense, such as swelling in the extremities and abdomen. This combination is relevant in settings marked by temporary physiological imbalance to help address the risk of low potassium levels (hypokalemia) that may occur. This feature assists with maintaining functional stability and contributes to easing the overall symptom load during symptomatic periods.

“This formulation helps patients cope more steadily during symptomatic phases linked to electrolyte imbalance and fluid management.”


Quick Fact: Relief for Swelling and Fluid Retention

Anza is commonly used to help manage the symptom cluster of visible swelling (edema), providing supportive relief that helps ease the overall symptom load associated with chronic volume overload.

Regulatory References

  1. DailyMed official label information

Eligibility and Restrictions for Use

Eligibility and Contraindications

Official regulatory documents define strict criteria for who can and cannot use Anza. The medicine is primarily established for use in adults (18 years and older) who are being treated for eligible conditions and are not subject to the following contraindications or restrictions.

Absolute Contraindications

The medicine must not be used in patients with:

  • Hyperkalemia (elevated serum potassium levels, typically above 5.5 mEq/liter).
  • Severe Renal Impairment or Severe Renal Disease (including anuria, acute renal failure, or diabetic nephropathy).
  • Concurrent use of Potassium-Conserving Agents (such as spironolactone or triamterene) or Potassium Supplements.
  • Known Hypersensitivity to either Amiloride, Hydrochlorothiazide, or any other sulfonamide-derived drugs.

Age and Reproductive Status

Anza is not recommended or contraindicated for pediatric patients (under 18) because safety and efficacy have not been established. It is not recommended during pregnancy (especially the second and third trimesters) or while breastfeeding.

Restricted Use

Use requires caution and frequent monitoring in patients with non-severe renal impairment, hepatic impairment, or certain comorbidities like Diabetes Mellitus, due to the heightened risk of serious electrolyte imbalance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Amiloride/Hydrochlorothiazide establishes several documented interaction patterns, primarily centered on pharmacokinetic exposure modification and pharmacodynamic effects on blood pressure and electrolytes.

Formal Interaction Restrictions

Co-administration with other potassium-sparing diuretics (such as spironolactone or triamterene) is strictly contraindicated due to the high risk of elevated serum potassium levels. This restriction also applies to medicinal potassium supplements and potassium-containing salt substitutes.

Documented Exposure and Effect Changes

The co-administration of lithium is documented to reduce its renal clearance, increasing the risk of lithium toxicity. Combining the product with ACE inhibitors or Angiotensin II Receptor Antagonists (ARBs) increases the risk of hyperkalemia. Furthermore, NSAIDs are documented to reduce the diuretic and antihypertensive effects of the medication. Substances such as alcohol or narcotics may potentiate orthostatic hypotension.

Administration Timing Rule

To prevent interference with absorption, the drug requires time separation from bile acid sequestrants (such as cholestyramine or colestipol resins). These resins must be administered at least one hour before or four hours after this combination product.

Population-Specific Notes

The risk of interaction-related hyperkalemia is officially noted as being higher in patients with impaired renal function or diabetes mellitus.

Mechanism of Action

Inhibition of Sodium Reabsorption at Two Distal Renal Sites

The core mechanism involves the simultaneous inhibition of sodium ( Na^+) transport at two distinct locations in the kidney's distal nephron: the Na^+/ Cl^- Cotransporter ( NCC) in the distal convoluted tubule and the Epithelial Sodium Channel ( ENaC) in the collecting duct. This blockade prevents the reabsorption of salt back into the bloodstream, resulting in Na^+ and chloride ( Cl^-) excretion (Natriuresis).


Modulation of Renal Osmotic Gradient and Volume

By increasing the amount of salt retained in the kidney tubules, the medication leverages the natural osmotic gradient, causing water to follow the salt out of the body in the urine (Diuresis). This process of fluid and salt loss decreases the total volume of fluid circulating systemically (Extracellular Fluid Volume, or ECFV), serving as the core physiological change resulting from the mechanism.


Mechanistic Counterbalance for Electrolyte Control

The combination includes a compensating mechanism, where the Amiloride component reduces the potassium ( K^+) loss influenced by the Hydrochlorothiazide component. By blocking ENaC, Amiloride reduces the electrical driving force needed for K^+ secretion, thereby affecting K^+ flux across the cell membrane during volume reduction.

Dosage and Administration Information

How Anza is Used: Official Administration Guidelines

Anza, the fixed-dose combination of Amiloride and Hydrochlorothiazide, is administered exclusively via the oral route as a tablet. The official usage instructions establish a standardized, long-term protocol for its consumption, defining the appropriate dosage, frequency, and administration context.

The medicine is designed to be taken once daily, a frequency pattern established to support consistent patient adherence. To ensure proper absorption and to minimize potential gastrointestinal effects, the tablets should be administered with food.

Standard Dosing and Administration Schedule

Instruction Detail (Strictly Label-Based)
Route of administration: Oral (by mouth).
Starting Dose (Adults): 1 tablet (5 mg Amiloride / 50 mg HCTZ) once daily.
Maximum Recommended Dose: 2 tablets (10 mg/100 mg) daily.
Dosing Schedule Note: Doses of two tablets daily may be given in divided doses.

Population-Specific Use Principles

Usage patterns are adjusted for certain populations as outlined in clinical protocols. For older adults, careful dosage adjustment is necessary, and treatment may begin with a lower dose, such as 1/2 to 1 tablet per day, due to considerations of varying physiological capacity. The medicine is not recommended for use in children under 18 years of age, as safety and efficacy have not been formally established for this group.

This structured administration protocol defines the conditions for the medicine's long-term management use, requiring adherence to the oral route, the once-daily schedule, the maximum dose limit, and the specific requirement of intake with food.

Recent Clinical Evidence

Research evidence / Overview of studies for Anza

Evidence for use in Essential Hypertension

The evidence base for Anza's use in essential hypertension primarily relies on Randomized Controlled Trials (RCTs) and comparative studies. Research explored how this fixed-dose combination was associated with changes in blood pressure measures when applied in adults with mild to moderate high blood pressure. These studies monitored outcomes related to systemic imbalance, focusing on the study of blood pressure measures and the observation of patterns related to potassium levels in the blood.

Findings describe patterns observed in the studies related to changes in measured blood pressure. Specifically, research examined the role of the Amiloride component, which is potassium-sparing, in relation to measured serum potassium levels during trials, compared to the thiazide component (Hydrochlorothiazide) alone. The research highlights measured changes during the study period, primarily focusing on the short-term evolution of blood pressure and electrolyte status over defined time intervals.

Some limitations are noted in the evidence landscape. Many of the pivotal efficacy trials for this specific combination are considered older research. Furthermore, long-term effects are not fully established regarding cardiovascular outcomes over many years. The existing studies provide limited information for long-term outcomes beyond the initial measurement periods, meaning follow-up durations were limited primarily to examining short-term changes.


Evidence for use in Systemic Fluid Overload (Edema)

The evidence base relies on a combination of clinical studies referenced in official labeling, high-quality observational data, and post-marketing surveillance reports. Research explored fluid retention or swelling (edema) in populations experiencing fluid accumulation associated with conditions marked by functional limitations, such as congestive heart failure. Studies monitored outcomes reflecting systemic or functional imbalance, specifically evaluating changes in visible swelling and measuring patterns related to diuresis (fluid output).

The research describes patterns observed in the studies related to the use of the combination in research exploring how symptoms change over time related to fluid volume. Findings describe patterns observed in the studies related to measured potassium levels in studies conducted during periods of increased symptom activity where fluid excretion was being observed. The studies report how symptoms evolved in the observed populations when applied in research contexts involving fluid volume.

It is important to note that comparative evidence is lacking in some areas; there are a limited number of recent RCTs directly comparing this combination against newer therapeutic options for fluid management. Research often describes the medication's role in an adjunctive capacity, meaning its use is primarily studied alongside other core treatments, and its independent contribution may appear to be less fully defined.

Key Studies & References

  1. The effect of amiloride/hydrochlorothiazide combination vs furosemide plus potassium supplementation in the treatment of oedema of cardiac origin
  2. Amiloride Hydrochloride and Hydrochlorothiazide Tablets, USP (Official Drug Label/Prescribing Information)
  3. Amiloride - StatPearls (Overview of Indications and Use with Thiazides)

Frequently Asked Questions (FAQ)

Common questions about Anza (FAQ)


Q: Why might a healthcare provider choose Anza over other standard treatments?

The use of Anza is based on the synergistic action of its two components. Official product information indicates that the pairing is intended to help maintain a more stable level of potassium in the body while achieving fluid and blood pressure reduction. This combination strategy is a known method to help stabilize key electrolytes.


Q: Is Anza considered a medicine with potential for dependence or habit-forming behavior?

Official documents regarding this medicine do not link it to the central nervous system dependence found in some other drug classes. However, it is noted that diuretics like Anza can be subject to misuse in certain contexts. This classification relates to the documented misuse of diuretics for effects such as rapid weight loss, rather than traditional addiction risk.


Q: Does Anza interact with common over-the-counter pain or cold relievers?

Caution is necessary when combining Anza with certain over-the-counter (OTC) products. Combining the medicine with non-steroidal anti-inflammatory drugs (NSAIDs) or certain cold and flu agents (sympathomimetics) may require extra monitoring. Patients are advised to inform their healthcare provider about all OTC medicines they are taking.


Q: Does Anza interact with widely used herbal supplements like St. John's Wort?

According to patient counseling guides, individuals should inform their healthcare provider about all vitamins, supplements, and herbal products used. This is advised because interactions with Anza are possible. Disclosing this information supports the healthcare provider's efforts to manage the treatment safely and effectively.


Q: What is the typical timeframe before the effects of Anza are noticed?

Studies indicate that the diuretic effect, or water-reducing action, of Anza typically begins quickly. This action is usually noticed within 1 to 2 hours after taking the tablet. The overall effect from a single dose is sustained for approximately 24 hours.


Q: Is Anza generally considered appropriate for older adults (seniors)?

Anza is generally considered appropriate for use in older adults (seniors). However, due to the higher likelihood of age-related changes in organ function, this population may require careful dosage adjustments when initiating treatment. Dosage adjustments are determined by the healthcare provider based on the patient's physiological status.


Q: Does Anza need to be taken at the exact same time every day for the best outcome?

Official patient guidelines recommend establishing a routine for taking this medicine. Taking the tablet around the same time every day is suggested to help ensure consistent adherence and support stable effectiveness throughout the treatment period.


Q: Is there any information on how Anza affects sleep patterns?

Official side effect lists include details about how Anza may affect the nervous system. The medication has been reported to cause drowsiness (somnolence). Less commonly, sleeplessness (insomnia) is also listed as a potential adverse event.


Q: What should a patient do if they accidentally take more Anza than prescribed?

Taking more than the prescribed amount of Anza can result in an overdose. Symptoms to watch for may include severe dizziness, fainting, a slow or irregular heartbeat, drowsiness, or extreme irritability. If an overdose is suspected, seeking immediate medical attention is important.


Q: Do the side effects of Anza typically decrease or go away over time?

Some temporary side effects are common when starting treatment with Anza. Official warnings note that side effects such as dizziness and lightheadedness are most frequently reported during the initiation period.


Q: Are there any known long-term safety concerns associated with taking Anza?

Long-term use of this medicine is associated with a specific safety concern. Official precautions indicate that prolonged use of the hydrochlorothiazide component has been associated with an increased risk for certain types of non-melanoma skin cancer (basal and squamous cell carcinoma).


Q: Can Anza potentially cause problems with major organs like the liver or kidneys?

Anza is contraindicated for use in patients with severe kidney problems. For all patients, the label lists signs of potential harm to major organs, including signs of liver problems (such as yellowing skin) or kidney problems (such as a significant change in the amount of urine).


Q: What signs might indicate a rare but serious side effect from Anza?

Rare but serious side effects require immediate attention. Official safety information advises watching for specific signs, including a slow or irregular heartbeat (which can indicate high potassium levels), fainting, or signs of liver problems such as yellowing of the eyes or skin.


Q: Does official evidence suggest Anza can cause weight changes?

The side effect list for Anza does include information on weight changes. Weight gain is reported as a less common adverse event associated with taking the medication.


Q: Are there any specific foods or drinks that should be avoided while taking Anza?

Regulatory precautions list specific dietary items to avoid while using Anza. Patients are advised to avoid using salt substitutes that contain potassium, as the amiloride component is potassium-sparing. Additionally, a diet excessively high in salt should be avoided.


Q: Could Anza affect the action or effectiveness of hormonal birth control?

There is regulatory information about the amiloride component's interaction with hormonal birth control. The use of this medicine is specifically contraindicated with certain progestin-containing oral contraceptives, such as those containing drospirenone, due to an increased risk of high potassium levels (hyperkalemia).


Q: What information is available regarding what to do if Anza does not seem to be helping?

If a patient is using Anza and their underlying condition does not seem to improve, patient information advises seeking guidance. Patients are advised to notify their healthcare provider if their symptoms do not get better or if they worsen while taking the medicine.


Q: How does missing a single dose of Anza generally impact the overall treatment effectiveness?

Official guidelines provide specific instructions for managing a missed dose. These instructions typically advise taking the missed dose if remembered soon, or skipping it if the next dose is due, without taking two doses at once. Patients should refer to their provided patient information for exact steps.


Q: Can people who have pre-existing heart problems use Anza?

People with pre-existing heart problems may use Anza. It is indicated for use in certain patients with congestive heart failure. However, conditions like high cholesterol or coronary artery disease may require caution and close monitoring during treatment.


Q: Are there any generic versions of Anza currently available or approved?

Yes, the combination product Amiloride/Hydrochlorothiazide, which is the composition of Anza, is widely available. Regulatory agencies confirm that approved generic versions of this combination product exist.


Q: Where can patients access the official, full prescribing information for Anza?

The full prescribing details and official patient labeling for Anza are public documents. Patients can access the official labeling, such as the Package Insert or Prescribing Information, through public government databases like DailyMed or the manufacturer’s patient information resources.

How should Anza be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory information for Anza (aprepitant) defines specific temperature and handling requirements to maintain stability. Oral capsules and tablets must typically be stored at controlled room temperature (20 C to 25 C). Prepared oral suspension and injectable vials require refrigeration (2 C to 8 C), and the injectable product must be protected from freezing.

Product Form Storage Temperature Stability Constraint
Oral Capsules/Tablets 20 C to 25 C Keep in original container
Prepared Suspension 2 C to 8 C (Refrigerated) Discard after 72 hours

All forms must be stored out of the reach of children. Unused or expired medication should be disposed of in accordance with applicable local regulations to ensure proper waste management and minimize environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anza found in:

A-Z Index: